• Intellia Therapeutics recently reported positive phase III results for its CRISPR therapy lonvoguran ziclumeran in hereditary angioedema and began a rolling BLA submission to the FDA, while the FDA also lifted clinical holds on its other phase III candidate, nexiguran ziclumeran, allowing those trials to resume.
• These twin milestones not only move Intellia’s in vivo CRISPR programs closer to potential commercialization but also reduce clinical and regulatory uncertainty around its most important late-stage assets.
• We’ll now examine how the rolling BLA for lonvoguran ziclumeran may reshape Intellia’s investment narrative and risk-reward profile.

Uncover the next big thing with 23 elite penny stocks that balance risk and reward.

Intellia Therapeutics Investment Narrative Recap

To own Intellia, you need to believe that one time in vivo CRISPR treatments for hereditary angioedema and ATTR can eventually support a real commercial business despite ongoing losses and dilution. The lonvoguran ziclumeran rolling BLA now looks like the key near term catalyst, while nexiguran’s history of liver related concerns remains the biggest risk even after the FDA lifted clinical holds and allowed phase III trials to restart.

Among recent announcements, the April 2026 follow on equity offering of roughly US$180.0 million stands out in this context. It reinforces that Intellia is still funding late stage development through shareholders rather than product revenue, which can matter if lonvoguran’s path through the FDA faces delays or if nexiguran needs additional data, prolonging the period of cash burn.

Yet behind the positive trial headlines, investors should also be aware that...

Intellia Therapeutics' narrative projects $814.8 million revenue and $16.7 million earnings by 2029. This requires 131.0% yearly revenue growth and an earnings increase of about $411 million from -$394.6 million today.

Uncover how Intellia Therapeutics' forecasts yield a $26.70 fair value, a 95% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were modeling revenue of about US$6.0 billion and earnings of US$1.9 billion by 2029, a far more aggressive path than consensus, and you can now decide whether the recent lonvoguran and nexiguran updates bring Intellia closer to that scenario or highlight why opinions on its risk and reward differ so widely.

Explore 4 other fair value estimates on Intellia Therapeutics - why the stock might be a potential multi-bagger!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Intellia Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Intellia Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Intellia Therapeutics' overall financial health at a glance.

Curious About Other Options?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The latest GPUs need a type of rare earth metal called Terbium and there are only 29 companies in the world exploring or producing it. Find the list for free.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Capitalize on the AI infrastructure supercycle with our selection of the 47 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.